Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 May;68(2):348–356.

Natural killer and activated killer activities in chronic liver disease and hepatocellular carcinoma: evidence for a decreased lymphokine-induced activity of effector cells.

H Hirofuji 1, S Kakumu 1, A Fuji 1, Y Ohtani 1, K Murase 1, H Tahara 1
PMCID: PMC1542719  PMID: 2820634

Abstract

Natural killer (NK) and activated killer (AK) cells appear to be important in immunoregulation, elimination of virus-infected cells and resistance to tumours. NK activity against K 562 and AK activity against FL target cells of peripheral blood mononuclear cells (PBMC) from patients with chronic persistent hepatitis (CPH), chronic active hepatitis (CAH), liver cirrhosis (LC) and hepatocellular carcinoma (HCC) were investigated using 51Cr release assay. Spontaneous NK activity of patients with LC (P less than 0.05) and HCC (P less than 0.001) was decreased when compared to that of controls. The sera and PBMC from patients with low NK activity had no inhibitory effect on the NK activity of normal subjects. Indomethacin treatment significantly enhanced the NK activity of controls (P less than 0.05), whereas the drug did not affect that of patients with low NK activity. The percentages of PBMC that reacted with monoclonal antibodies anti-Leu-7 and anti-Leu-11a were similar in controls and patients. However, a Leu-11a+/Leu-7+ ratio, and NK activity of Leu-11+ and Leu-7+ cell-rich populations were significantly decreased in cirrhotic and HCC patients when compared to controls. Interleukin 2 boosted both NK and AK activities of patients, but to a lesser degree in comparison with those of controls when similarly stimulated. gamma-Interferon also significantly augmented NK and AK activities of patients, but the levels of cytotoxicity were lower in HCC patients (P less than 0.05) than those of controls. These findings suggest that the decreased NK and AK activities in chronic liver disease and HCC are due to an altered subpopulation ratio of NK cells and a functional defect of effector cells.

Full text

PDF
348

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Charpentier B., Franco D., Paci L., Charra M., Martin B., Vuitton D., Fries D. Deficient natural killer cell activity in alcoholic cirrhosis. Clin Exp Immunol. 1984 Oct;58(1):107–115. [PMC free article] [PubMed] [Google Scholar]
  2. Goodwin J. S., Bankhurst A. D., Messner R. P. Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell. J Exp Med. 1977 Dec 1;146(6):1719–1734. doi: 10.1084/jem.146.6.1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Goto M., Tanimoto K., Chihara T., Horiuchi Y. Natural cell-mediated cytotoxicity in Sjögren's syndrome and rheumatoid arthritis. Arthritis Rheum. 1981 Nov;24(11):1377–1382. doi: 10.1002/art.1780241107. [DOI] [PubMed] [Google Scholar]
  4. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Henney C. S., Kuribayashi K., Kern D. E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature. 1981 May 28;291(5813):335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
  6. Herberman R. B., Holden H. T. Natural cell-mediated immunity. Adv Cancer Res. 1978;27:305–377. doi: 10.1016/s0065-230x(08)60936-7. [DOI] [PubMed] [Google Scholar]
  7. Hoffman T. Natural killer funciton in systemic lupus erythematosus. Arthritis Rheum. 1980 Jan;23(1):30–35. doi: 10.1002/art.1780230106. [DOI] [PubMed] [Google Scholar]
  8. Horwitz D. A., Kight N., Temple A., Allison A. C. Spontaneous and induced cytotoxic properties of human adherent mononuclear cells: killing of non-sensitized and antibody-coated non-erythroid cells. Immunology. 1979 Feb;36(2):221–228. [PMC free article] [PubMed] [Google Scholar]
  9. Itoh K., Shiiba K., Shimizu Y., Suzuki R., Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). J Immunol. 1985 May;134(5):3124–3129. [PubMed] [Google Scholar]
  10. Itoh K., Tilden A. B., Kumagai K., Balch C. M. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol. 1985 Feb;134(2):802–807. [PubMed] [Google Scholar]
  11. James S. P., Jones E. A. Abnormal natural killer cytotoxicity in primary biliary cirrhosis: evidence for a functional deficiency of cytolytic effector cells. Gastroenterology. 1985 Jul;89(1):165–171. doi: 10.1016/0016-5085(85)90758-9. [DOI] [PubMed] [Google Scholar]
  12. Kakumu S., Hara T., Gohji H., Sakamoto N. Inhibition of lymphocyte cytotoxicity in chronic active hepatitis. Clin Exp Immunol. 1978 Jul;33(1):71–78. [PMC free article] [PubMed] [Google Scholar]
  13. Kakumu S., Hara T., Goji H., Sakamoto N. Lymphocyte cytotoxicity against Chang liver cells in chronic active hepatitis. Cell Immunol. 1978 Mar 1;36(1):46–53. doi: 10.1016/0008-8749(78)90249-6. [DOI] [PubMed] [Google Scholar]
  14. Kakumu S., Yata K., Kashio T. Immunoregulatory T-cell function in acute and chronic liver disease. Gastroenterology. 1980 Oct;79(4):613–619. [PubMed] [Google Scholar]
  15. Lanier L. L., Benike C. J., Phillips J. H., Engleman E. G. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol. 1985 Feb;134(2):794–801. [PubMed] [Google Scholar]
  16. Lanier L. L., Le A. M., Phillips J. H., Warner N. L., Babcock G. F. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983 Oct;131(4):1789–1796. [PubMed] [Google Scholar]
  17. Marx J. L. Natural killer cells help defend the body. Science. 1980 Nov 7;210(4470):624–626. doi: 10.1126/science.6159684. [DOI] [PubMed] [Google Scholar]
  18. Mulé J. J., Shu S., Schwarz S. L., Rosenberg S. A. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984 Sep 28;225(4669):1487–1489. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  19. Nakamura T., Morizane T., Watanabe T., Tsuchimoto K., Inagaki Y., Kumagai N., Tsuchiya M. Decreased natural killer activity in patients with liver cirrhosis. Int J Cancer. 1983 Nov 15;32(5):573–575. doi: 10.1002/ijc.2910320509. [DOI] [PubMed] [Google Scholar]
  20. Oshimi K., Oshimi Y., Satake M., Mizoguchi H. Natural killer-mediated lysis of normal and malignant target cells, and its regulation by monocytes. J Exp Med. 1985 Aug 1;162(2):472–486. doi: 10.1084/jem.162.2.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Phillips J. H., Warner N. L., Lanier L. L. Correlation of biophysical properties and cell surface antigenic profile of Percoll gradient-separated human natural killer cells. Nat Immun Cell Growth Regul. 1983;3(2):73–86. [PubMed] [Google Scholar]
  22. Rosenberg S. A. Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep. 1984 Jan;68(1):233–255. [PubMed] [Google Scholar]
  23. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985 Dec 5;313(23):1485–1492. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  24. Son K., Kew M., Rabson A. R. Depressed natural killer cell activity in patients with hepatocellular carcinoma. In vitro effects of interferon and levamisole. Cancer. 1982 Dec 15;50(12):2820–2825. doi: 10.1002/1097-0142(19821215)50:12<2820::aid-cncr2820501222>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  25. Trinchieri G., Matsumoto-Kobayashi M., Clark S. C., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984 Oct 1;160(4):1147–1169. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Trinchieri G., Santoli D., Koprowski H. Spontaneous cell-mediated cytotoxicity in humans: role of interferon and immunoglobulins. J Immunol. 1978 Jun;120(6):1849–1855. [PubMed] [Google Scholar]
  27. Verhoef J., Sharma S. D. Inhibition of human natural killer activity by lysosomotropic agents. J Immunol. 1983 Jul;131(1):125–131. [PubMed] [Google Scholar]
  28. Weigent D. A., Stanton G. J., Johnson H. M. Interleukin 2 enhances natural killer cell activity through induction of gamma interferon. Infect Immun. 1983 Sep;41(3):992–997. doi: 10.1128/iai.41.3.992-997.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES